Outcomes of 25-Gauge Vitrectomy for Tractional and Nontractional Diabetic Macular Edema with Proliferative Diabetic Retinopathy

Table 2

Comparison of the eyes with and without visual acuity improvement in the two groups.

	Improvement	No improvement
TME group	23 eyes	33 eyes
Baseline general conditions
Mean age (year)	55.5 ± 9.4 [38–69]	59.0 ± 9.2 [40–74]	0.09
Sex (male/female)	12/11	24/9	0.19
Diabetic duration (year)	11.0 ± 11.0 [1–30]	12.5 ± 12.3 [1–41]	0.27
HbA1c (%)	7.4 ± 1.9 [5.3–11.6]	7.9 ± 1.7 [6.4–13.3]	0.059
eGFR (ml/m)	55.0 ± 28.7 [0.93–96]	56.7 ± 35.8 [0.5–112]	0.48
Hypertension	16	18	0.26
Anticoagulant use	5	2	0.18
Baseline ocular conditions
Mean LogMAR	1.34 ± 0.65 [2.7–0.2]	0.83 ± 0.70 [2.7–0]	0.003
Mean CMT (μm)	603 ± 162 [356–801]	413 ± 195 [150–1008]	0.005
Lens status (IOL/phakia)	0/23	3/30	0.25
Ocular hypertension	1	3	0.38
Vitreous hemorrhage	17	14	0.019
Tractional retinal detachment	6	5	0.31
Adjunctive intravitreal anti-VEGF injection	8	8	0.58
Retinal photocoagulation	14	25	0.23
nTME group	47 eyes	13 eyes
Baseline general conditions
Mean age (year)	57.9 ± 13.9 [30–77]	61.8 ± 15.0 [42–81]	0.18
Sex (male/female)	27/20	9/4	0.65
Diabetic duration (years)	9.5 ± 8.3 [1–30]	14.7 ± 14.1 [1–46]	0.18
HbA1c (%)	8.0 ± 1.8 [4.8–11.8]	7.5 ± 1.0 [6.4–10.2]	0.19
eGFR (ml/m)	61.6 ± 41.0 [0.5–111]	66.1 ± 40.8 [0.55–110]	0.32
Hypertension	33	10	0.90
Anticoagulant use	3	1	0.64
Baseline ocular conditions
Mean LogMAR	1.47 ± 0.67 [2.7–0.22]	0.51 ± 0.45 [1.4–0.05]	<0.001
Mean CMT (μm)	429 ± 186 [148–811]	363 ± 97 [242–988]	0.19
Lens status (IOL/phakia)	12/35	2/11	0.69
Ocular hypertension	1	0	0.21
Vitreous hemorrhage	43	9	0.037
Tractional retinal detachment	4	1	0.92
Adjunctive intravitreal anti-VEGF injection	10	1	0.06
Retinal photocoagulation	36	10	0.98

Data are expressed as number of eyes or patients or mean ± standard deviation [low–high].